Navigation Links
Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer

roof of the principle for the therapeutic application of targeted ADVEXIN therapy in tumors with p53 abnormalities that are among the most common and fundamental molecular defects in cancer," said Neil Senzer, M.D., Scientific Director, Mary Crowley Medical Research Center, and lead author of the article. "ADVEXIN's mechanism of action is targeted to restoring p53 tumor suppressor function that is abnormal in Li-Fraumeni tumors and in many other types of cancer."

ADVEXIN is being developed for European markets by Gendux AB, a subsidiary of Introgen Therapeutics, Inc. The European Medicines Agency (EMEA) has designated, and the European Union has confirmed, ADVEXIN p53 therapy as an Orphan Drug for the treatment of LFS. A Letter of Intent to the EMEA regarding Marketing Authorization Application for the approval of ADVEXIN to treat LFS was filed under the Exceptional Circumstances Approval procedures in the EU.

Collaborators on this publication included clinicians from Mary Crowley Medical Research Center, Sammons Cancer Center, Baylor University Medical Center, The Royal Marsden Hospital NHS Foundation Trust, Imperial College London Hammersmith Campus, and the Institute of Cancer Research in the United Kingdom.

About Li-Fraumeni Syndrome

Approximately 400 families are affected by LFS annually. The majority of LFS families contain mutations in the p53 tumor suppressor gene. Affected individuals often develop multiple primary tumors, which typically occur at a young age. Conventional therapy of patients with the Li-Fraumeni Syndrome is frequently unsuccessful due to the occurrence of multiple malignancies that share a common p53 genetic defect fundamental to cancer progression and the development of treatment resistance. Defects in p53-mediated cell death pathways cause these tumors to develop resistance to standard therapy, resulting in early death. Additionally, because affected individuals lack p53-mediated DNA repair function, treatment
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
(Date:7/31/2015)... 2015  Xcelience, a contract development and manufacturing ... a structured cash investment in Powdersize, a ... micronization and powder size classification within the pharmaceutical ... while simultaneously adding a complete set of particle ... "As we continue to build ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... represented by ICAP Ocean Tomo , this technology discloses an ... portfolio will be auctioned off at ICAP Ocean Tomo,s Spring ... York City. (Logo: https://photos.prnewswire.com/prnh/20100614/CG20517LOGO ) ... discloses the following: An advanced hip implant ...
... 15, 2011 Survey Sampling International (SSI)—the ... sampling solutions—has appointed Chris DeAngelis to head ... support the unique sampling requirements of health-related ... of sampling science to health-focused industries, SSI ...
Cached Medicine Technology:Healthier Healing for Hip Resurfacing - ICAP Ocean Tomo Announces Auction of an Advanced Hip Cap for Electromagnetic Tissue Stimulation by Neue Magnetodyn. 2Survey Sampling International Names Chris DeAngelis to Head New SSI Health 2Survey Sampling International Names Chris DeAngelis to Head New SSI Health 3
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – ... trek of the Appalachian Trail by stepping off Springer Mountain and heading north. ... On July 26th Phil reached Connecticut and was greeted by friends and family. He ...
(Date:7/31/2015)... , ... August 01, 2015 , ... Super Bowl 50 will emanate from ... League’s biggest day each year is the Super Bowl. In the two weeks that separate ... from the host venue. The 2016 Super Bowl game will mark the 50th time it ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride ... in Downtown Memphis on October 3, 2015. The Ride to Fight On is a ... research between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... of a new malaria vaccine on both humans and ... disease that causes at least one million deaths annually, ... the Pasteur Institute here injected an MSP-3-based vaccine into ... it after one month and again after four months, ...
... from National Cancer Institute, US is to start testing their ... drug metabolize, enzyme kinetics and drug action mechanisms in dogs ... ,Dr. Chand Khanna, Veterinary Oncologist said, “It turns out that ... represented in dogs and the dogs will help us prioritize ...
... very good ones nutritionally due to their numerous benefits and ... of stroke, according to an article published in the Oct. ... of seven prospective studies, five from the US, one from ... of 232,049 subjects - 90,513 men and 141,536 women - ...
... new research conducted in Helsinki, Finland, gluten-free diet ... adolescents with coeliac disease.,Coeliac disease in adolescents has ... and disruptive behavioural disorders, particularly in the phase ... 9 adolescents with coeliac disease, aged 12 to ...
... There has been an increasing focus to change work ... and relaxation to avoid mental illness and its devastating ... acceptable one in view of the results published by ... the impact of anxiety and depressive disorders on workplace ...
... claimed to be of the first of its kind, ... in a young child with attention-deficit/hyperactivity disorder//. ... of the journal Pediatrics, present the case report of ... hyperactivity, attention deficit, impulsivity, and sleep problems. ...
Cached Medicine News:Health News:Breakthrough In New Vaccine For Malaria 2Health News:Servings of fruits can help reduce the risk of stroke 2Health News:Gluten-Free Diet May Alleviate Psychiatric Symptoms In Adolescents 2Health News:Now Employers Focus On Employees Mental health 2Health News:Iron Supplementation Aid In Relief From Attention-Deficit/Hyperactivity Disorder 2
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
Medicine Products: